To what extent can preventive treatments prevent damage from systemic lupus erythematosus?

Curr Rheumatol Rep. 2011 Aug;13(4):317-23. doi: 10.1007/s11926-011-0188-4.

Abstract

Managing lupus patients traditionally involves treating manifestations of active disease with the most effective and least toxic therapies so that "damage" from ongoing disease or treatments can be minimized. Damage in clinical epidemiologic studies is usually defined by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, a validated, organ-specific assessment tool. This review summarizes recent developments regarding organ-specific manifestations and lupus-related damage and their prevention.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / physiopathology
  • Disability Evaluation
  • Endocrine System Diseases / epidemiology
  • Endocrine System Diseases / physiopathology
  • Gastrointestinal Diseases / epidemiology
  • Gastrointestinal Diseases / physiopathology
  • Glucocorticoids / therapeutic use*
  • Health Status Indicators
  • Humans
  • Kidney Diseases / epidemiology
  • Kidney Diseases / physiopathology
  • Lung Diseases / epidemiology
  • Lung Diseases / physiopathology
  • Lupus Erythematosus, Systemic / drug therapy*
  • Lupus Erythematosus, Systemic / epidemiology
  • Lupus Erythematosus, Systemic / physiopathology
  • Lupus Vasculitis, Central Nervous System / complications
  • Lupus Vasculitis, Central Nervous System / epidemiology
  • Morbidity
  • Severity of Illness Index
  • Skin Diseases / epidemiology
  • Skin Diseases / physiopathology

Substances

  • Glucocorticoids